MBX Biosciences, Inc. Financing Cash Flow
MBX Biosciences, Inc. (MBX) reported Financing Cash Flow of $89.76 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-06
- MBX Biosciences, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $2.32M, a 75.04% increase year-over-year.
- MBX Biosciences, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $87.44M, a 2185775.00% increase year-over-year.
- MBX Biosciences, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $438.00K.
- MBX Biosciences, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $187.82M, a 20.35% decline year-over-year.
- MBX Biosciences, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $189.59M, a 19.01% decline from fiscal 2024.
- MBX Biosciences, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $234.10M, a 238.21% increase from fiscal 2023.
- MBX Biosciences, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $69.22M.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $89.76M 10-Q · filed 2026-08-06 | $90.19M derived: sum of 3 quarters · filed 2026-08-06 | $278.02M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $87.44M 10-Q · filed 2026-05-07 | $87.87M derived: sum of 2 quarters · filed 2026-05-07 | $275.70M derived: sum of 3 quarters · filed 2026-05-07 | $277.02M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $438.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $188.26M derived: sum of 2 quarters · filed 2026-03-12 | $189.59M derived: sum of 3 quarters · filed 2026-08-06 | $189.59M 10-K · filed 2026-03-12 |
| 2025-09-30 | $187.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $189.15M derived: sum of 2 quarters · filed 2026-08-06 | $189.15M 10-Q · filed 2025-11-06 | $189.02M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $1.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.33M 10-Q · filed 2026-08-06 | $1.20M derived: sum of 3 quarters · filed 2026-08-06 | $237.01M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $4.00K 10-Q · filed 2026-05-07 | -$128.00K derived: sum of 2 quarters · filed 2026-05-07 | $235.69M derived: sum of 3 quarters · filed 2026-05-07 | $233.93M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$132.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $235.68M derived: sum of 2 quarters · filed 2026-03-12 | $233.92M derived: sum of 3 quarters · filed 2026-03-12 | $234.10M 10-K · filed 2026-03-12 |
| 2024-09-30 | $235.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $234.05M derived: sum of 2 quarters · filed 2025-11-06 | $234.24M 10-Q · filed 2025-11-06 | $234.25M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$1.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$1.58M 10-Q · filed 2025-08-07 | -$1.56M derived: sum of 3 quarters · filed 2025-08-07 | |
| 2024-03-31 | $183.00K 10-Q · filed 2025-05-12 | $202.00K derived: sum of 2 quarters · filed 2025-05-12 | ||
| 2023-12-31 | $19.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $69.22M 10-K · filed 2025-03-17 | ||
| 2023-09-30 | $69.20M 10-Q · filed 2024-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |